
|Articles|April 4, 2016
Disease Interception and the US National Cancer Moonshot
Author(s)DIA
Advertisement
In the US, patients, caregivers and advocates, drug developers and the FDA have moved towards a patient-centered approach to drug development. The National Cancer Moonshot, a task force led by Vice President Joseph Biden, includes this patient-centric strategy in its agenda: Seeking to facilitate collaborations with researchers, doctors, philanthropies, patients, patient advocates, and biotechnology and pharmaceutical companies to accelerate the early detection and treatment of cancer, its goal is a decade’s worth of advances in five years.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook
2
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
3
Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff
4
FDA Rejects AstraZeneca’s Application for Subcutaneous Indication of Saphnelo
5



